Impact of Therapy on Plasma Myeloperoxidase in Patients with Coronary Artery Disease

Impact of Therapy with Statins, Beta-blockers and Angiotensin-converting Enzyme Inhibitors on Plasma Myeloperoxidase in Patients with Coronary Artery Disease
Journal: Clinical Research in Cardiology (October 20, 2010)
Authors: Ndrepepa G, Braun S, Schömig A, Kastrati A
Purpose: The authors analyzed blood samples of a 680-patient cohort “with angiographically confirmed CAD: 382 patients with stable CAD, 107 patients with unstable angina and 191 patients with ST-segment elevation acute myocardial infarction” in order to investigate “whether therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on admission affects the plasma level of myeloperoxidase in patients with coronary artery disease.”
Results: “On admission, 316 patients were receiving statins, 432 patients were receiving beta-blockers and 354 patients were receiving ACE inhibitors.” Though beta-blockers were “independently associated with lower levels of plasma myeloperoxidase,” researchers found that “pre-admission therapy with statins, beta-blockers or ACE inhibitors reduced MPO levels in patients with acute coronary syndromes, but not in patients with stable CAD.”
http://hcp.lv/9WQL9O